ResMed launches AirTouch F40 mask in U.S.

ResMed has introduced the AirTouch F40 full-face continuous positive airway pressure mask for the United States market, with availability scheduled to begin on 28 October 2026. The product uses a fabric cushion and is designed as part of ResMed’s sleep and breathing therapy portfolio. This launch follows the publication of the company’s FY26 financial results and comes ahead of its planned Q1 FY27 earnings report.

The AirTouch F40 extends an existing range of mask designs offered by ResMed. The new design is aligned with the company’s broader work on enhancing patient comfort and supporting ongoing use of therapy. By adding another full-face option, ResMed broadens the choices available to patients and clinicians within its CPAP mask lineup.

The AirTouch F40 is a full-face CPAP mask that incorporates a fabric cushion component. This approach fits into ResMed’s emphasis on comfort features that may help patients tolerate and continue long-term therapy. The mask is intended for use in continuous positive airway pressure treatment, a standard approach for sleep-related breathing disorders.

By positioning the AirTouch F40 within its existing mask family, ResMed is refining its hardware offering rather than entering a new therapy area. The mask sits alongside other designs and interfaces in the company’s range of devices, masks, digital tools and software for care delivered outside hospitals.

In FY26, ResMed reported revenue of USD 5.653 billion, an increase of 10%. Net income for the year reached USD 1.523 billion, compared with USD 1.401 billion. The company also recorded higher sales, operating income and net earnings as it moved into FY27.

These financial results form the backdrop for the AirTouch F40 launch in the U.S. market. ResMed entered FY27 following a year of growth in its core therapy and software businesses, and the new mask adds to the portfolio of products that support sleep and breathing care.

ResMed develops devices, masks, digital tools and software used primarily outside hospital settings, with a focus on sleep and breathing therapy. The introduction of the AirTouch F40 in October 2026 aligns with ongoing changes in its therapy hardware and software portfolio through product updates and transactions.

On 22 October 2026, ResMed shares were quoted at AUD 34.835, down 0.16% in that trading session. This share move occurred as the company prepared for the U.S. availability of the AirTouch F40 and after it had published FY26 financial results showing growth in revenue and net income.